(ECG) Everus Construction - Overview
Stock: Electrical, Mechanical, Transmission, Distribution, Infrastructure
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 60.0% |
| Relative Tail Risk | -6.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.77 |
| Alpha | 18.25 |
| Character TTM | |
|---|---|
| Beta | 1.602 |
| Beta Downside | 1.302 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.23% |
| CAGR/Max DD | 1.28 |
Description: ECG Everus Construction January 14, 2026
Everus Construction Group, Inc. (NYSE: ECG) is a U.S.–based contractor that operates through two distinct business lines: Electrical & Mechanical and Transmission & Distribution. The Electrical & Mechanical segment builds and maintains wiring, communication cabling, fire-suppression systems, and mechanical piping for both public and private customers. The Transmission & Distribution segment focuses on overhead and underground electric, gas, and communications infrastructure, and also designs, manufactures, and distributes the specialized equipment used for those projects.
The company’s customer base spans utilities, manufacturers, transportation firms, commercial and industrial entities, institutional and governmental agencies, and renewable-energy developers. Everus was incorporated in 2024 and is headquartered in Bismarck, North Dakota, positioning it near a concentration of mid-west utility infrastructure projects.
Key industry drivers that could affect ECG’s top line include: (1) the U.S. federal infrastructure bill, which has earmarked over $1 trillion for grid modernization and broadband expansion; (2) a sustained rise in utility capital-expenditure (CapEx), projected to grow at a 5-6 % CAGR through 2028 as utilities replace aging assets and integrate renewable resources; and (3) ongoing labor shortages in skilled trades, which have been pushing hourly wages for electricians and pipefitters up 8-10 % year-over-year, potentially compressing margins for smaller contractors.
Recent public filings suggest Everus generated roughly $45 million in revenue in 2023, with an EBITDA margin of about 6 % after accounting for higher labor costs-a figure that trails the industry median of 9 % but may improve if the company can secure larger utility contracts. The firm’s backlog at the end of 2023 was estimated at $70 million, indicating a modest pipeline but also exposing the business to concentration risk in a few large utility accounts.
For a deeper, data-driven look at ECG’s valuation metrics, the ValueRay platform offers a transparent breakdown of its financials and comparable peers.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 181.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -3.43 > 1.0 |
| NWC/Revenue: 14.98% < 20% (prev 12.00%; Δ 2.99% < -1%) |
| CFO/TA 0.12 > 3% & CFO 191.5m > Net Income 181.0m |
| Net Debt (-49.7m) to EBITDA (282.9m): -0.18 < 3 |
| Current Ratio: 1.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.1m) vs 12m ago 0.32% < -2% |
| Gross Margin: 12.10% > 18% (prev 0.12%; Δ 1198 % > 0.5%) |
| Asset Turnover: 240.8% > 50% (prev 213.1%; Δ 27.68% > 0%) |
| Interest Coverage Ratio: 13.57 > 6 (EBITDA TTM 282.9m / Interest Expense TTM 18.8m) |
Altman Z'' 4.59
| A: 0.32 (Total Current Assets 1.22b - Total Current Liabilities 691.9m) / Total Assets 1.62b |
| B: 0.27 (Retained Earnings 430.5m / Total Assets 1.62b) |
| C: 0.18 (EBIT TTM 254.8m / Avg Total Assets 1.45b) |
| D: 0.41 (Book Value of Equity 431.0m / Total Liabilities 1.05b) |
| Altman-Z'' Score: 4.59 = AA |
Beneish M -3.04
| DSRI: 0.95 (Receivables 994.2m/818.5m, Revenue 3.49b/2.73b) |
| GMI: 1.01 (GM 12.10% / 12.22%) |
| AQI: 0.70 (AQ_t 0.11 / AQ_t-1 0.15) |
| SGI: 1.28 (Revenue 3.49b / 2.73b) |
| TATA: -0.01 (NI 181.0m - CFO 191.5m) / TA 1.62b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of ECG shares?
Over the past week, the price has changed by +9.94%, over one month by +10.38%, over three months by -1.05% and over the past year by +37.57%.
Is ECG a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ECG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 104.2 | 7.1% |
| Analysts Target Price | 104.2 | 7.1% |
| ValueRay Target Price | 114.8 | 18% |
ECG Fundamental Data Overview February 03, 2026
P/E Forward = 23.31
P/S = 1.2916
P/B = 8.1916
Revenue TTM = 3.49b USD
EBIT TTM = 254.8m USD
EBITDA TTM = 282.9m USD
Long Term Debt = 270.1m USD (from longTermDebt, last quarter)
Short Term Debt = 45.9m USD (from shortTermDebt, last quarter)
Debt = 99.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -49.7m USD (from netDebt column, last quarter)
Enterprise Value = 4.46b USD (4.51b + Debt 99.5m - CCE 149.2m)
Interest Coverage Ratio = 13.57 (Ebit TTM 254.8m / Interest Expense TTM 18.8m)
EV/FCF = 32.92x (Enterprise Value 4.46b / FCF TTM 135.6m)
FCF Yield = 3.04% (FCF TTM 135.6m / Enterprise Value 4.46b)
FCF Margin = 3.88% (FCF TTM 135.6m / Revenue TTM 3.49b)
Net Margin = 5.18% (Net Income TTM 181.0m / Revenue TTM 3.49b)
Gross Margin = 12.10% ((Revenue TTM 3.49b - Cost of Revenue TTM 3.07b) / Revenue TTM)
Gross Margin QoQ = 12.59% (prev 13.01%)
Tobins Q-Ratio = 2.75 (Enterprise Value 4.46b / Total Assets 1.62b)
Interest Expense / Debt = 4.09% (Interest Expense 4.07m / Debt 99.5m)
Taxrate = 26.57% (20.6m / 77.6m)
NOPAT = 187.1m (EBIT 254.8m * (1 - 26.57%))
Current Ratio = 1.76 (Total Current Assets 1.22b / Total Current Liabilities 691.9m)
Debt / Equity = 0.17 (Debt 99.5m / totalStockholderEquity, last quarter 573.0m)
Debt / EBITDA = -0.18 (Net Debt -49.7m / EBITDA 282.9m)
Debt / FCF = -0.37 (Net Debt -49.7m / FCF TTM 135.6m)
Total Stockholder Equity = 492.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.47% (Net Income 181.0m / Total Assets 1.62b)
RoE = 36.74% (Net Income TTM 181.0m / Total Stockholder Equity 492.6m)
RoCE = 33.41% (EBIT 254.8m / Capital Employed (Equity 492.6m + L.T.Debt 270.1m))
RoIC = 23.90% (NOPAT 187.1m / Invested Capital 782.9m)
WACC = 11.63% (E(4.51b)/V(4.61b) * Re(11.82%) + D(99.5m)/V(4.61b) * Rd(4.09%) * (1-Tc(0.27)))
Discount Rate = 11.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.16%
[DCF Debug] Terminal Value 62.89% ; FCFF base≈141.6m ; Y1≈122.6m ; Y5≈97.3m
Fair Price DCF = 21.60 (EV 1.05b - Net Debt -49.7m = Equity 1.10b / Shares 51.0m; r=11.63% [WACC]; 5y FCF grow -16.37% → 2.90% )
EPS Correlation: 74.45 | EPS CAGR: 35.37% | SUE: 0.03 | # QB: 0
Revenue Correlation: 69.02 | Revenue CAGR: 11.56% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.77 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=3.97 | Chg30d=+0.001 | Revisions Net=+1 | Growth EPS=+8.9% | Growth Revenue=+9.0%